Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ixekizumab deemed effective for pityriasis rubra pilaris

Publish date:: July 24, 2020

Key clinical point: Ixekizumab appears to be safe and effective for treatment of longstanding pityriasis rubra pilaris.

Major finding: Of 11 patients, 7 achieved at least a 50% reduction in disease signs and symptoms.

Study details: This was an open-label, 24-week, single-arm clinical trial of ixekizumab in 11 patients with longstanding pityriasis rubra pilaris.

Disclosures: The presenter reported receiving research funding from Eli Lilly, the study sponsor, as well as from Janssen Scientific Affairs.

Citation:

Greiling T. AAD 2020.

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

More severe AD correlates with worse sleep health and attention problems in children,

Shortcomings identified in study of acne videos on TikTok,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Must Reads in Medical Dermatology

New lupus classification criteria perform well in children, young adults,

Phone outreach intervention feasible to reduce SLE readmissions,

Age, smoking among leading cancer risk factors for SLE patients,

Cachexia affects more than half of lupus patients,

Ixekizumab deemed effective for pityriasis rubra pilaris,